A multicenter clinical randomized phase II study of investigating duration of adjuvant chemotherapy with S-1 (six versus 12 months) for patients with resected pancreatic cancer: PACS-1 study.

Yo-ichi Yamashita,Shinji Itoh,Mototsugu Shimokawa,Hiroshi Takamori,Kengo Fukuzawa,Mizuki Ninomiya,Kenichiro Araki,Kiyoshi Kajiyama,Keishi Sugimachi,Hideaki Uchiyama,Yuji Morine,Tohru Utsunomiya,Tadashi Uwagawa,Takashi Maeda,Eisuke Adachi,Yasuharu Ikeda,Tomoharu Yoshizumi,Hideo Baba,Masaki Mori

A multicenter clinical randomized phase II study of investigating duration of adjuvant chemotherapy with S-1 (six versus 12 months) for patients with resected pancreatic cancer: PACS-1 study.

2020

Yo-ichi Yamashita
Shinji Itoh
Mototsugu Shimokawa
Hiroshi Takamori
Kengo Fukuzawa
Mizuki Ninomiya
Kenichiro Araki
Kiyoshi Kajiyama
Keishi Sugimachi
Hideaki Uchiyama
Yuji Morine
Tohru Utsunomiya
Tadashi Uwagawa
Takashi Maeda
Eisuke Adachi
Yasuharu Ikeda
Tomoharu Yoshizumi
Hideo Baba
Masaki Mori

669Background: Although adjuvant chemotherapy with S-1 has improved overall survival and progression-free survival (PFS) in patients with resected pancreatic cancer, the duration evaluation of adju...

Keywords:

Pancreatic cancer
Phases of clinical research
Internal medicine
Oncology
Medicine
Chemotherapy
Adjuvant
Pathology
in patient
adjuvant chemotherapy
overall survival

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations